UCB Seeks FDA Approval For Cimzia In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
The biologic, which has yet to obtain a Crohn’s indication in the U.S. and Europe, is backed by efficacy data from three Phase III trials in RA.
You may also be interested in...
Cimzia Rheumatoid Arthritis Approval Held Up By Safety Request
UCB receives “complete response” letter from FDA on second indication for the biologic, approved for Crohn’s disease with a REMS.
Cimzia Rheumatoid Arthritis Approval Held Up By Safety Request
UCB receives “complete response” letter from FDA on second indication for the biologic, approved for Crohn’s disease with a REMS.
J&J/Centocor Files Golimumab In Three Indications
Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.